查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474896

核准的药物测试 (LDT) 市场规模、份额、趋势分析报告：按技术、按应用、按地区、细分市场预测，2024-2030 年

Laboratory Developed Tests Market Size, Share & Trends Analysis Report By Technology (Immunoassay, Molecular Diagnostics), By Application (Oncology, Nutritional & Metabolic Disease), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

核准药物检测 (LDT) 市场的成长和趋势：

Grand View Research, Inc.最新报告预测，到2030年，全球核准药物试验（LDT）开发市场规模将达到198.5亿美元，2024年至2030年复合年增长率为7.05%。

该行业的成长得益于慢性病、遗传疾病、感染疾病和自体免疫疾病的日益流行，以及人们健康生活意识的不断增强。核准药物测试 (LDT) 最常用于分子诊断，除了遗传学之外，还包括各种不同化学物质的测试。

例如，2022年7月，Quest Diagnostics推出了基于实验室的分子诊断测试，用于诊断猴痘病毒感染。此外，由于新测试的开发，免疫测量正在获得广泛的采用和接受。例如，2021 年 12 月，OPKO Health, Inc. 宣布 FDA 批准 4Kscore 测试，这是一种 LDT，将四种免疫检测整合为一个数字评分，并考虑了患者年龄、切片检查和已公布的直肠核准检结果。 LDT 不需要 FDA核准，因为它们不出售给其他人，但它们必须经过严格的验证程序。然而，全球癌症盛行率的增加是推动该产业成长的关键因素。

根据 GLOBOCAN 估计，2020 年全球预计将新增 1,930 万癌症病例，其中 230 万是乳癌病例。肺癌是癌症患者最常见的死亡原因，因此该领域对更快、更准确的诊断工具的需求尚未得到满足。 2021 年 1 月，英国体外诊断协会要求英国 NHS 开发癌症分子诊断的委託框架。主要企业正专注于产品发布和地理扩张，以获取更高的行业份额。例如，2022 年 5 月，Guardant Health 推出了 Shield，这是一种血液检测，可用作 LDT，以检测 45 岁及以上成年人口中结直肠癌的早期迹象。

核准药物测试 (LDT) 市场报告重点：

  • 分子诊断技术领域在该行业中占据主导地位，并在 2023 年占整体销售额的最大份额。
  • 该领域的成长是由于对许多疾病提供诊断测试的需求增加。
  • 由于癌症盛行率的增加，预计癌症应用领域在预测期内将显着增长。
  • 由于创新服务的推出可以满足目标受众不断增长的需求，预计该市场将大幅成长。
  • 由于新型LDT产品的推出以及老年人口不断增长对诊断工具的高需求，北美将在2023年占据该行业的主导地位。

目录

第一章核准的药物测试（LDT）市场：调查方法与范围

第 2 章核准的药物测试 (LDT) 市场：执行摘要

  • 市场展望
  • 分部展望
  • 竞争考察

第三章核准药物测试 (LDT) 市场：变数、趋势、范围

  • 市场体系展望
  • 市场动态
  • 核准的药物测试（LDT）市场分析工具

第四章核准的药物测试（LDT）市场：技术评估和趋势分析

  • 2023年及2030年技术市场占有率
  • 细分仪表板
  • 全球核准药物测试（LDT）市场，按技术分類的前景
  • 2018-2030年市场规模、预测及趋势分析

第五章核准的药物测试（LDT）市场：应用估算和趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 全球核准药物测试（LDT）市场，依应用前景
  • 2018-2030年市场规模、预测及趋势分析

第六章核准的药物测试（LDT）市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测及趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • Quest Diagnostics Incorporated.
    • 23andMe, Inc.
    • Abbott
    • Guardant Health
    • NeoGenomics Laboratories.
    • QIAGEN
    • Siemens Healthineers AG
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-4-68040-010-5

Laboratory Developed Tests Market Growth & Trends:

The global laboratory developed tests market size is expected to reach USD 19.85 billion by 2030, expanding at a CAGR of 7.05% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the industry is attributed to the increasing prevalence of chronic and genetic diseases, infectious & autoimmune diseases, and rising awareness among the population about healthy living. The laboratory-developed tests (LDTs) are generated and utilized in the laboratories, and LDTs are released into the market without FDA approval or any other independent regulatory assessment. LDTs are most typically employed in molecular diagnostics, which includes tests that target a variety of different chemicals in addition to genetics.

For instance, in July 2022, Quest Diagnostics launched a lab-based molecular diagnostic test for the diagnosis of monkeypox virus infections. Moreover, immunoassay is gaining immense adoption and acceptability with the development of novel tests. For instance, in December 2021, OPKO Health, Inc., announced the FDA approval of the 4Kscore test, an LDT in which, four immunoassays are combined into a single numerical score that takes into account the patient's age, biopsy history, and the results of a digital rectal exam. Although LDTs do not require FDA approval as they are not marketed to others, they need to go through rigorous validation procedures. However, the increasing global prevalence of cancer is a key factor driving the industry's growth.

According to GLOBOCAN, in 2020, there were an estimated 19.3 million new cancer cases globally, out of which, 2.3 million were breast cancer cases. Lung cancer was the most common cause of death among cancer patients, representing an unmet need for faster and more accurate diagnostic tools in the segment. In January 2021, the British In Vitro Diagnostics Association urged NHS England for the development of a commissioning framework for molecular diagnostics in oncology. Key players focus on product launches and geographical expansion to gain a higher industry share. For instance, in May 2022, Guardant Health launched Shield, a blood test that is available as an LDT for the detection of early signs of colorectal cancer in the adult population aged above 45 years

Laboratory Developed Tests Market Report Highlights:

  • The molecular diagnostic technology segment dominated the industry and accounted for the largest share of the overall revenue in 2023
  • The segment growth was attributed to the increased need to provide diagnostics tests for a number of diseases
  • The oncology application segment is expected to grow lucratively over the forecast period due to the increasing prevalence of cancer
  • The market is expected to grow significantly owing to the introduction of innovative services that can address the growing demands of the target audience
  • North America dominated the industry in 2023 owing to the introduction of novel LDT products and the high demand for diagnostics tools with the increasing geriatric population

Table of Contents

Chapter 1. Laboratory Developed Tests Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Application
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Laboratory Developed Tests Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Laboratory Developed Tests Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing demand for in vitro diagnostic tests that are currently unavailable in the market
      • 3.2.1.2. Increasing demand for development of personalized medicine
      • 3.2.1.3. No requirement for any regulatory approval
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with the laboratory-developed test
      • 3.2.2.2. Efficacy and safety issues related to LDT
  • 3.3. Laboratory Developed Tests (LDT) Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Laboratory Developed Tests (LDT) Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Laboratory Developed Tests (LDT) Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Immunoassays
      • 4.4.1.1. Immunoassays market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Hematology and Coagulation
      • 4.4.2.1. Hematology and coagulation market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Molecular Diagnostics
      • 4.4.3.1. Molecular diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Microbiology
      • 4.4.4.1. Microbiology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Clinical Chemistry
      • 4.4.5.1. Clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Histology/Cytology
      • 4.4.6.1. Histology/Cytology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Flow Cytometry
      • 4.4.7.1. Flow Cytometry market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.8. Mass Spectroscopy
      • 4.4.8.1. Mass spectroscopy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.9. Others
      • 4.4.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Laboratory Developed Tests (LDT) Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Laboratory Developed Tests (LDT) Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Oncology
      • 5.4.1.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Genetic Disorders/Inherited Disease
      • 5.4.2.1. Genetic disorders/Inherited disease market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Infectious & Parasitic Diseases
      • 5.4.3.1. Infectious & parasitic diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Immunology
      • 5.4.4.1. Immunology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. Endocrine
      • 5.4.5.1. Endocrine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.6. Nutritional & Metabolic Disease
      • 5.4.6.1. Nutritional & metabolic disease market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.7. Cardiology
      • 5.4.7.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.8. Mental/Behavioral Disorder
      • 5.4.8.1. Mental/Behavioral disorder market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.9. Pediatrics-specific Testing
      • 5.4.9.1. Pediatrics-specific testing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.10. Hematology/General Blood Testing
      • 5.4.10.1. Hematology/General blood testing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.11. Bodily Fluid Analysis
      • 5.4.11.1. Bodily fluid analysis market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.12. Toxicology
      • 5.4.12.1. Toxicology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.13. Other Diseases
      • 5.4.13.1. Other diseases market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Laboratory Developed Tests (LDT) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Quest Diagnostics Incorporated.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. 23andMe, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Abbott
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Guardant Health
      • 7.3.7.1. Company overview
      • 7.3.7.2. Product benchmarking
      • 7.3.7.3. Strategic initiatives
    • 7.3.8. NeoGenomics Laboratories.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. QIAGEN
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Siemens Healthineers AG
      • 7.3.10.1. Company overview
      • 7.3.10.2. Product benchmarking
      • 7.3.10.3. Strategic initiatives
    • 7.3.11. Illumina, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Product benchmarking
      • 7.3.11.3. Strategic initiatives
    • 7.3.12. F. Hoffmann-La Roche Ltd.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Product benchmarking
      • 7.3.12.3. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 6 U.S. laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 7 Canada laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 8 Canada laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 9 Europe laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Europe laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 12 Germany laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Germany laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 14 U.K. laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 15 U.K. laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 16 France laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 17 France laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 18 Italy laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Italy laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 20 Spain laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Spain laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 22 Denmark laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 23 Denmark laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 24 Sweden laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Sweden laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 26 Norway laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Norway laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 31 China laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 32 China laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 33 Japan laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 34 Japan laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 35 India laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 36 India laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 37 South Korea laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 38 South Korea laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 39 Australia laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 40 Australia laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 41 Thailand laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Thailand laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 43 Latin America laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Latin America laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 46 Brazil laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Brazil laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 48 Mexico laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Mexico laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 50 Argentina laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 51 Argentina laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 52 MEA laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 54 MEA laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Africa laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 56 South Africa laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 59 UAE laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 60 UAE laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 61 Kuwait laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 62 Kuwait laboratory developed tests market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Laboratory developed tests market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Laboratory developed tests market driver impact
  • Fig. 20 Laboratory developed tests market restraint impact
  • Fig. 21 Laboratory developed tests market strategic initiatives analysis
  • Fig. 22 Laboratory developed tests market: Technology movement analysis
  • Fig. 23 Laboratory developed tests market: Technology outlook and key takeaways
  • Fig. 24 Immunoassays market estimates and forecast, 2018 - 2030
  • Fig. 25 Hematology and coagulation estimates and forecast, 2018 - 2030
  • Fig. 26 Molecular diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 27 Microbiology market estimates and forecast, 2018 - 2030
  • Fig. 28 Clinical chemistry market estimates and forecast, 2018 - 2030
  • Fig. 29 Histology/Cytology market estimates and forecast, 2018 - 2030
  • Fig. 30 Flow cytometry market estimates and forecast, 2018 - 2030
  • Fig. 31 Mass spectroscopy market estimates and forecast, 2018 - 2030
  • Fig. 32 Others market estimates and forecast, 2018 - 2030
  • Fig. 33 Laboratory developed tests market: Application movement Analysis
  • Fig. 34 Laboratory developed tests market: Application outlook and key takeaways
  • Fig. 35 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 36 Genetic disorders/Inherited disease market estimates and forecasts, 2018 - 2030
  • Fig. 37 Infectious & parasitic diseases market estimates and forecasts, 2018 - 2030
  • Fig. 38 Immunology market estimates and forecasts, 2018 - 2030
  • Fig. 39 Endocrine market estimates and forecasts, 2018 - 2030
  • Fig. 40 Nutritional & metabolic disease market estimates and forecasts, 2018 - 2030
  • Fig. 41 Cardiology market estimates and forecasts, 2018 - 2030
  • Fig. 42 Mental/Behavioral disorder market estimates and forecasts, 2018 - 2030
  • Fig. 43 Pediatrics-specific testing market estimates and forecasts, 2018 - 2030
  • Fig. 44 Hematology/General blood testing market estimates and forecasts, 2018 - 2030
  • Fig. 45 Bodily fluid analysis market estimates and forecasts, 2018 - 2030
  • Fig. 46 Toxicology market estimates and forecasts, 2018 - 2030
  • Fig. 47 Other diseases market estimates and forecasts, 2018 - 2030
  • Fig. 48 Global laboratory developed tests market: Regional movement analysis
  • Fig. 49 Global laboratory developed tests market: Regional outlook and key takeaways
  • Fig. 50 Global laboratory developed tests market share and leading players
  • Fig. 51 North America market share and leading players
  • Fig. 52 Europe market share and leading players
  • Fig. 53 Asia Pacific market share and leading players
  • Fig. 54 Latin America market share and leading players
  • Fig. 55 Middle East & Africa market share and leading players
  • Fig. 56 North America: SWOT
  • Fig. 57 Europe SWOT
  • Fig. 58 Asia Pacific SWOT
  • Fig. 59 Latin America SWOT
  • Fig. 60 MEA SWOT
  • Fig. 61 North America market estimates and forecasts, 2018 - 2030
  • Fig. 62 U.S key country dynamics
  • Fig. 63 U.S market estimates and forecasts, 2018 - 2030
  • Fig. 64 Canada key country dynamics
  • Fig. 65 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 66 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 67 UK key country dynamics
  • Fig. 68 UK market estimates and forecasts, 2018 - 2030
  • Fig. 69 Germany key country dynamics
  • Fig. 70 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 71 France key country dynamics
  • Fig. 72 France market estimates and forecasts, 2018 - 2030
  • Fig. 73 Italy key country dynamics
  • Fig. 74 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 75 Spain key country dynamics
  • Fig. 76 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 77 Denmark key country dynamics
  • Fig. 78 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 79 Sweden key country dynamics
  • Fig. 80 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 81 Norway key country dynamics
  • Fig. 82 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 83 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 84 China key country dynamics
  • Fig. 85 China market estimates and forecasts, 2018 - 2030
  • Fig. 86 Japan key country dynamics
  • Fig. 87 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 88 India key country dynamics
  • Fig. 89 India market estimates and forecasts, 2018 - 2030
  • Fig. 90 Thailand key country dynamics
  • Fig. 91 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Korea key country dynamics
  • Fig. 93 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 94 Australia key country dynamics
  • Fig. 95 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 96 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 97 Brazil key country dynamics
  • Fig. 98 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 99 Mexico key country dynamics
  • Fig. 100 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 101 Argentina key country dynamics
  • Fig. 102 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 103 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 104 South Africa key country dynamics
  • Fig. 105 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 106 Saudi Arabia key country dynamics
  • Fig. 107 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 108 UAE key country dynamics
  • Fig. 109 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 110 Kuwait key country dynamics
  • Fig. 111 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 112 Market share of key market players- Laboratory developed tests market